What are the indications, dosing, composition, contraindications, side effects, and precautions for Neurostil (gabapentin) capsules?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 6, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Neurostil (Gabapentin) Capsules: Comprehensive Information

What is Neurostil?

Neurostil is the brand name for gabapentin, an antiepileptic medication that is FDA-approved for managing postherpetic neuralgia in adults and as adjunctive therapy for partial onset seizures with or without secondary generalization in adults and children 3 years and older. 1


Composition and Mechanism

  • Active ingredient: Gabapentin 1
  • Inactive ingredients: Mannitol, hydroxypropyl cellulose, crospovidone, talc, magnesium stearate, and Aquarius® BP18114 Cool Vanilla 1
  • Gabapentin is a structural analogue of GABA but has a mechanism of action distinct from GABA-related effects, though the exact mechanism remains incompletely understood 2, 3
  • The drug penetrates the CNS despite being a GABA analogue that typically does not cross the blood-brain barrier 3

FDA-Approved Indications

  1. Management of postherpetic neuralgia in adults 1
  2. Adjunctive therapy for partial onset seizures (with and without secondary generalization) in adults and pediatric patients 3 years and older with epilepsy 1

Off-Label Uses (Evidence-Based)

  • HIV-associated neuropathic pain: Gabapentin is recommended as first-line oral pharmacological treatment, titrated to a maximum of 2400 mg/day over 4 weeks 4
  • Diabetic peripheral neuropathy: Effective at doses of 1800-3600 mg/day, with 38% of patients achieving at least 50% pain reduction versus 21% with placebo 4, 5
  • Chronic neuropathic pain syndromes: Relieves allodynia, burning pain, shooting pain, and hyperesthesia 6

Dosing Guidelines

Standard Neuropathic Pain Dosing

Start gabapentin at 100-300 mg at bedtime on day 1, increase to 300 mg three times daily (900 mg/day) by day 3, then titrate upward by 300 mg every 3-7 days until reaching the target therapeutic dose of 1800-3600 mg/day in three divided doses. 7

  • Initial dose: 100-300 mg at bedtime or 300 mg once daily 4, 7
  • Day 1-3 titration: 300 mg on day 1,600 mg on day 2,900 mg on day 3 6
  • Target therapeutic dose: 1800 mg/day (600 mg three times daily) is the minimum effective dose for most neuropathic pain conditions 7
  • Maximum dose: 3600 mg/day (1200 mg three times daily) may be needed for optimal pain relief 7, 6
  • Dosing frequency: Three times daily administration is mandatory due to saturable, nonlinear absorption pharmacokinetics 7

Special Population Dosing

Elderly or medically frail patients:

  • Start at 100-200 mg/day with slower titration, increasing every 3-7 days or longer 7
  • Lower doses may be effective due to age-related decline in renal function 7
  • Mandatory renal function assessment before initiation 8

Renal impairment:

  • Dose adjustment is mandatory as gabapentin is eliminated primarily by renal excretion 4, 7
  • Dosing must be adjusted based on creatinine clearance values 4

Duration of Adequate Trial

  • Minimum trial duration: 3-8 weeks for titration plus 2 weeks at maximum tolerated dose 7
  • An adequate therapeutic trial may require 2 months or more, as efficacy develops gradually over several weeks 7

Administration Instructions

  • Gabapentin can be taken with or without food 1
  • If taking antacids containing aluminum and magnesium (Maalox®, Mylanta®, Gelusil®, Gaviscon®, Di-Gel®), wait at least 2 hours before taking the next dose of gabapentin 1
  • If a tablet is broken in half, the unused half should be taken at the next scheduled dose; discard unused half-tablets after 28 days 1
  • Never abruptly discontinue: Taper gradually over a minimum of 1 week to avoid withdrawal symptoms 7

Contraindications

Gabapentin is contraindicated in patients who have demonstrated hypersensitivity to the drug or its ingredients. 1


Side Effects

Common Adverse Effects (Occur in >10% of patients)

  • Dizziness (19%) 8, 5
  • Somnolence/drowsiness (14%) 8, 5
  • Lack of coordination 1
  • Fatigue/feeling tired 1
  • Gait disturbance (9%) 8
  • Peripheral edema (7%) 5
  • Nausea and vomiting 1
  • Difficulty with speaking 1
  • Tremor and jerky movements 1
  • Double vision and unusual eye movements 1

Serious Adverse Effects

  • Increased risk of suicidal thoughts or behavior: Like other antiepileptic drugs, gabapentin carries this risk 1
  • Respiratory depression: Serious breathing problems can occur when combined with opioids, benzodiazepines, or other CNS depressants 1
  • Neurologic toxicity: Particularly in patients with renal dysfunction due to drug accumulation 9
  • Speech impairment: Can occur due to CNS effects, especially in elderly patients 8
  • Increased fall risk: Due to dizziness, somnolence, and gait disturbance, particularly concerning in elderly patients 8

Adverse Event Withdrawal Rates

  • Adverse event withdrawals occur in 11% of gabapentin-treated patients versus 8.2% with placebo 5
  • Serious adverse events occur in 3.2% of gabapentin patients versus 2.8% with placebo 5
  • At least one adverse event occurs in 63% of gabapentin patients versus 49% with placebo 5

Precautions and Warnings

Before Starting Gabapentin

Inform your healthcare provider if you have: 1

  • Kidney problems or are on hemodialysis
  • Depression, mood problems, or history of suicidal thoughts or behavior
  • Diabetes
  • Are pregnant, planning to become pregnant, or breastfeeding

During Treatment

  • Do not drink alcohol or take other sedating medications without consulting your healthcare provider, as this may worsen sleepiness or dizziness 1
  • Do not drive or operate heavy machinery until you know how gabapentin affects you, as it can slow thinking and motor skills 1
  • Monitor for speech changes including slurred speech, reduced fluency, or changes in voice quality 8
  • Watch for signs of suicidal thoughts or behavior, especially when starting treatment or changing doses 1
  • Assess for fall risk, particularly in elderly patients experiencing dizziness or gait disturbance 8

Drug Interactions

  • Gabapentin is not protein-bound, is not metabolized, and does not induce liver enzymes, minimizing drug interactions 2, 3
  • However, caution is warranted when combining with other CNS-active medications 8
  • Antacids containing aluminum and magnesium can affect gabapentin absorption 1

Efficacy Data

Postherpetic Neuralgia

  • 32% of patients achieve substantial benefit (at least 50% pain relief) with gabapentin at 1200 mg daily or greater versus 17% with placebo (NNT 6.7) 5
  • 46% achieve moderate benefit (at least 30% pain relief) versus 25% with placebo (NNT 4.8) 5

Painful Diabetic Neuropathy

  • 38% achieve substantial benefit with gabapentin at 1200 mg daily or greater versus 21% with placebo (NNT 5.9) 5
  • 52% achieve moderate benefit versus 37% with placebo (NNT 6.6) 5

Refractory Partial Seizures

  • Gabapentin (600-1800 mg/day) reduces seizure frequency by ≥50% in 18-28% of patients with refractory partial seizures 3
  • Overall seizure frequency decreases by 18-32% during 3-month treatment periods 3

Storage

  • Store gabapentin at 20°-25°C (68°-77°F) 1
  • Keep out of reach of children 1

Pregnancy and Breastfeeding

  • Pregnancy: It is not known if gabapentin can harm an unborn baby; discuss risks and benefits with your healthcare provider 1
  • Pregnant patients should consider enrolling in the North American Antiepileptic Drug (NAAED) Pregnancy Registry by calling 1-888-233-2334 1
  • Breastfeeding: Gabapentin passes into breast milk; discuss feeding options with your healthcare provider 1

Critical Clinical Pearls

  • Three times daily dosing is mandatory for standard gabapentin due to nonlinear, saturable absorption 7
  • Efficacy develops gradually over several weeks; allow adequate trial duration before declaring treatment failure 7
  • Start low and go slow in elderly patients to minimize fall risk from dizziness 7, 8
  • Somnolence was reported by 80% of patients in HIV neuropathy trials at 2400 mg/day 4
  • About 3-4 out of 10 patients achieve worthwhile pain relief, while over half will not have adequate response but may experience adverse events 5

Reporting Adverse Events

  • Report side effects to FDA at 1-800-FDA-1088 1
  • For questions about gabapentin or to report side effects, contact Camber Pharmaceuticals, Inc. at 1-866-495-8330 1

References

Research

Gabapentin: a unique anti-epileptic agent.

Neurological research, 2001

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Gabapentin for chronic neuropathic pain in adults.

The Cochrane database of systematic reviews, 2017

Guideline

Gabapentin Dosing Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Gabapentin-Induced Speech Impairment

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Research

Gabapentin-induced neurologic toxicities.

Pharmacotherapy, 2005

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.